definiens: within the meaning of The Private Securities Litigation Reform Act of1995, including statements regarding the timing of filing of the biologics license application for XIAFLEX for the treatmentof Dupuytren ’s contracture with the U.S. Food and Drug Administration ; the timing of filing for approval for XIAFLEX for thetreatment of Dupuytren ’s contracture in Europe ; the timing of results from the Phase IIb trial for XIAFLEX for the treatment ofPeyronie ’s ; [COMPANY] ’s ability to develop, register for approval and commercialize XIAFLEX for Dupuytren ’s contracture andPeyronie ’s disease in the licensed territory ; [COMPANY] ’s receipt of milestone payments and royalties from [COMPANY] ; the benefits ofthe strategic alliance between [COMPANY] and [COMPANY] ; the potential benefits and effectiveness of XIAFLEX for Dupuytren’scontracture and Peyronie ’s disease ; the number of people suffering from Dupuytren ’s contracture and Peyronie ’s disease ; andall other statements containing projections, statements of future performance or expectations, or statements of plans orobjectives for future operations ( including statements of assumption underlying or relating to any of the foregoing ) . You canidentify these statements by the fact that they use words such as and other words and terms of similar meaning in connectionwith any discussion of projections, future performance or expectations, plans or objectives for future operations ( includingstatements of assumption underlying or relating to any of the foregoing ) . Actual results may differ materially from thosereflected in these forward - looking statements due to various factors, including further evaluation of clinical data, results ofclinical trials, decisions by regulatory authorities as to whether and when to approve drug applications, and general financial, economic, regulatory and political conditions affecting the biotechnology and pharmaceutical industries and those discussedin [COMPANY] ’s Annual Report on Form 10 - K for the year ended December 31, 2007 and in [COMPANY] ’s Quarterly Report onForm 10 - Q for the period ended September 30, 2008 under the heading, which are on file with the Securitiesand Exchange Commission ( the ) and may be accessed electronically by means of the SEC ’s home page on the Internetat http://www.sec.gov or by means of [COMPANY] ’s home page on the Internet at http://www.Auxilium.com under the heading There may be additional risks that [COMPANY] does not presently know or that Auxiliumcurrently believes are immaterial which could also cause actual results to differ from those contained in the forward - lookingstatements . Given these risks and uncertainties, any or all of these forward - looking statements may prove to be incorrect